spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PROMUS 

 HSMN NewsFeed - 27 Oct 2021
HT Supreme(R) Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Jun 2020
Quest Products, LLC Acquires Summit Pharmaceuticals / Alliance Labs, Including Enemeez(R) and DocuSol(R) Brands
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Sep 2019
Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019
Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2018
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 13 May 2016
Boston Scientific Announces Schedule of Presentations at EuroPCR 2016
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2014
Boston Scientific Reports Strong Performance Data For SYNERGY(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 1 May 2014
Boston Scientific Launches Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Dec 2013
Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2013
Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2013
Boston Scientific Promus PREMIER(TM) and SYNERGY(TM) Drug-Eluting Stent Systems Provide Exceptional Safety and Efficacy Data
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2013
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 17 May 2013
Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013
Devices Interventional Cardiology
 HSMN NewsFeed - 7 May 2013
OrbusNeich enforces injunction against Boston Scientific in Germany
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 30 Apr 2013
OrbusNeich obtains preliminary injunction in patent infringement proceedings in Germany against Boston Scientific
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 8 Mar 2013
OrbusNeich File Patent Infringement Lawsuit Against Boston Scientific in Ireland
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 20 Feb 2013
OrbusNeich Files Patent Infringement Actions Against Boston Scientific in Germany and the Netherlands
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 30 Nov 2012
First Patient Enrolled in the Boston Scientific Multicenter Study of the SYNERGY(TM) Coronary Stent System Featuring a Bioabsorbable Polymer Coating
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Oct 2012
Boston Scientific Receives CE Mark Approval for the SYNERGY(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, Featuring A Novel Bioabsorbable Polymer Coating
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 24 Oct 2012
PROMUS Element(TM) and PROMUS Element(TM) Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 23 Oct 2012
The Boston Scientific PROMUS Element(TM) Platinum Chromium Stent Demonstrates Positive Outcomes in Patients with Long Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Jun 2012
Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element(TM) Plus Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 18 May 2012
PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY(TM) Stent Versus PROMUS Element(TM) Platinum Chromium Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 May 2012
Boston Scientific Announces Schedule For EuroPCR 2012
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Mar 2012
Boston Scientific Announces Launch of PROMUS Element(TM) Platinum Chromium Stent System in Japan
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 23 Feb 2012
Boston Scientific Announces First Implants of TELIGEN(R) Implantable Defibrillator in China
Devices Cardiology
 HSMN NewsFeed - 1 Feb 2012
Boston Scientific Announces First Implant and Market Launch of PROMUS Element(TM) Plus Stent System in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Jan 2012
Boston Scientific Announces Favorable Ruling in Patent Infringement Case
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 1 Nov 2011
Boston Scientific Announces Schedule of Events at TCT Scientific Symposium
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Oct 2011
Boston Scientific Launches Promus Element™ Stent System In China
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Oct 2011
Boston Scientific Begins Clinical Trial Enrollment for OMEGA(TM) Platinum Chromium Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Jun 2011
Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 25 May 2011
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS(R) 2.25 mm Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2011
PROMUS Element Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Apr 2011
Boston Scientific Announces FDA Approval and U.S. Launch of ION Platinum Chromium Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 4 Apr 2011
Boston Scientific's Promus Element Platinum Chromium Stent System Demonstrates Comparable Safety And Effectiveness Outcomes Versus Leading Drug-Eluting Stent In Platinum Workhorse Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Apr 2011
Medtronic Resolute(R) Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Mar 2011
Medtronic to Unveil Pivotal U.S. Data on Resolute(R) Drug-Eluting Stent at ACC.11
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Mar 2011
Boston Scientific Announces European Approval and Launch of OMEGA Platinum Chromium Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Feb 2011
Boston Scientific Launches PROMUS(R) Element and TAXUS(R) Element Stent Systems in India
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2011
Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Jan 2011
Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY Drug-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Boston Scientific's TAXUS(R) Element Stent Demonstrates Strong Outcomes in Diabetic Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Sep 2010
PROMUS(R) Element Stent Approved for Use in Diabetic and Heart Attack Patients in CE Mark Countries
Devices Regulatory Interventional Cardiology
 HSMN NewsFeed - 3 Aug 2010
Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent with Bioabsorbable Polymer and Everolimus Drug Coating
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jun 2010
Boston Scientific Announces European Launch and First Implants of Platinum Chromium TAXUS(R) Element Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 26 May 2010
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2010
Boston Scientific Announces Schedule for EuroPCR 2010
Devices Interventional Cardiology
 HSMN NewsFeed - 12 May 2010
Boston Scientific Announces European Approval of Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
Boston Scientific Completes Enrollment in PLATINUM Trials for Small Vessels and Long Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Mar 2010
PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS(R) Element(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2010
Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes
Devices Litigation Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2010
Boston Scientific Settles Longstanding Patent Disputes With J&J
Devices Litigation Interventional Cardiology
 HSMN NewsFeed - 20 Jan 2010
Court Finds J&J Patents Invalid
Devices Interventional Cardiology Litigation
 HSMN NewsFeed - 8 Jan 2010
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 2 Nov 2009
Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Sep 2009
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2009
Boston Scientific Announces Schedule for EuroPCR 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2009
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2009
Boston Scientific Announces Schedule For ACC 2009
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Feb 2009
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 4 Feb 2009
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Oct 2008
Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Oct 2008
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Sep 2008
Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 2 Jun 2008
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 14 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Apr 2008
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Devices Interventional Cardiology
 HSMN NewsFeed - 31 Mar 2008
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Mar 2008
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Feb 2008
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
Devices Reimbursement Interventional Cardiology
 HSMN NewsFeed - 29 Nov 2007
Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Jul 2007
Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2007
Boston Scientific Announces Schedule for EuroPcr 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Spirit III Clinical Trial Demonstrates Positive Performance for Both TAXUS(R) and PROMUS(TM) Drug-Eluting Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Mar 2007
Boston Scientific Announces Schedule for ACC 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2007
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2006
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
Devices Interventional Cardiology
 HSMN NewsFeed - 25 Oct 2006
Data in Complex Patients and Lesions from OLYMPIA Registry Support Safety and Efficacy of TAXUS(R) Liberte(TM) Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 18 Oct 2006
Boston Scientific to Highlight Broad Range of Clinical Trial Results Reinforcing Safety and Efficacy of TAXUS(R) Coronary Stent Systems at TCT 2006
Devices Interventional Cardiology
 HSMN NewsFeed - 16 Oct 2006
Boston Scientific Becomes only Company with Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System
Devices Interventional Cardiology Regulatory
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
PROMUS
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.